Texas 2011 - 82nd Regular

Texas Senate Bill SB996

Voted on by Senate
 
Out of House Committee
 
Voted on by House
 
Governor Action
 
Bill Becomes Law
 

Caption

Relating to establishing a pill splitting program to reduce health plan costs for certain public employees.

Impact

The bill amends certain sections of the Insurance Code, specifically Subchapters E, D, and C, by introducing rules for the implementation of the pill splitting program. This initiative is expected to offer significant cost reductions for public employees who may benefit from reduced copayments when participating in the program. It targets the rising costs associated with prescription medications and aims to promote the responsible use of medications that are suitable for splitting, potentially leading to broader healthcare savings for the state.

Summary

Senate Bill 996 establishes a voluntary pill splitting program aimed at reducing health plan costs for certain public employees in Texas. The bill mandates that participating individuals must obtain a prescription from their physician for eligible prescription pills that can be split. It provides an incentive program where copayments are reduced for participants, encouraging their engagement in the program. Eligibility is determined based on a list of prescriptions that are deemed appropriate for splitting, which is maintained by a designated committee under the bill's provisions.

Sentiment

Overall, the sentiment surrounding SB996 appears to be positive, with supporters highlighting its potential to save money for state employees and improve healthcare access. There is a general acknowledgment of the rising prescription drug costs, and this bill seeks to address those challenges. However, some concerns may arise from the responsibility placed on individuals to split their medications safely, which could pose risks if not executed properly. Nonetheless, it is viewed as a proactive step in managing healthcare expenditures.

Contention

While not highly contentious, the bill does bring forth considerations regarding patient safety and the adequacy of guidelines for pill splitting. Stakeholders may question the effectiveness of implementing such a program without comprehensive educational support for participants. Concerns may also be raised about the accountability measures for manufacturers concerning liability in the event of adverse health outcomes related to pill splitting. Nevertheless, the legislation includes provisions to protect manufacturers from civil or criminal liabilities, which may alleviate some reservations voiced by pharmaceutical companies.

Companion Bills

TX HB762

Identical Relating to establishing a pill splitting program to reduce health plan costs for certain public employees.

Previously Filed As

TX HB762

Relating to establishing a pill splitting program to reduce health plan costs for certain public employees.

Similar Bills

TX HB762

Relating to establishing a pill splitting program to reduce health plan costs for certain public employees.

PA HB69

Further providing for title and short title of act, for definitions, for establishment, for restocking and dispensing of cancer drugs, for storage, distribution and fees and for immunity; providing for annual report and for list of approved participating pharmacies; further providing for regulations; and imposing duties on the State Board of Pharmacy.

NM SB122

Expand Prescription Drug Donation Program

TX SB1243

Relating to a pilot program for donation and redistribution of certain unused prescription medications; authorizing a fee.

GA HB931

Health; control high costs of prescription drugs; establish framework

MN HF1093

Commissioner of human services directed to establish a prescription drug purchasing program, program authority and eligibility requirements specified, and recommendations required.

TX HB25

Relating to wholesale importation of prescription drugs in this state; authorizing a fee.

ME LD697

An Act to Direct the Maine Prescription Drug Affordability Board to Assess Strategies to Reduce Prescription Drug Costs and to Take Steps to Implement Reference-based Pricing